|Dosage and administration||
Hypersensitivity to any of component of this product.
|Warnings and precautions for use||
Potassium levels in the blood should be monitored, especially in the elderly and patients with renal insufficiency. A lower starting dose is recommended in these patients.
|Recommendation for pregnancy and breastfeeding||
|Effects on ability to drive and use machines||
It should be taken into account that dizziness or drowsiness due to hypotension may occasionally occur when taking antihypertensive therapy. Therefore, caution should be taken when driving, using machine or engaging in activities that require complete alertness.
|Interactions, incompatibilities of medicine||
Data on the safety and efficacy of the combination of telmisartan and ACE inhibitors or beta-adrenergic blocking agents, have not been established. Telmisartan may increase the blood pressure lowering effect of these drugs. Do not co-administer aliskiren with telmisartan in patients with diabetes (ClCr < 60 ml/min).
|Undesirable effects (ADRs)||
ADRs have generally been mild and transient in nature and have infrequently required discontinuation of therapy.
|Overdose and management||
There is limited information available with regard to overdose in humans.
Telmisartan is a benzimidazole derivative and a non-peptide angiotensin II receptor antagonist with antihypertensive property. Telmisartan selectively antagonizes angiotensin II binding to the angiotensin II AT1 subtype receptor, located in vascular smooth muscle and adrenal gland.
Absorption: Telmisartan is rapidly absorbed from the gastrointestinal tract. The absolute oral bioavailability of telmisartan is dose dependent: At 40 and 160 mg dose the bioavailability was 42% and 58%, respectively. Food slightly reduces the bioavailability of telmisartan (with a reduction of about 6% after a 40 mg dose). Following oral administration, peak plasma concentrations of telmisartan are reached in 0.5 to 1 hour after dosing.
|Storage conditions, shelf-life, quality specification of the medicine||
Storage conditions: Protect from humidity and light, below 30 degrees C.
Composition: Each tablet contains:
Telmisartan . . . . . . . . . . . . . . . . . . . . . . . 80 mg
4 blisters of 7 film-coated tablets in a carton box.
Agimstan 80 containing telmisartan is indicated in:
Treatment of hypertension: Telmisartan may be used alone or in combination with other classes of antihypertensives for the treatment of hypertension.
Agimstan 80 tablets are used to replace ACE inhibitors in the treatment of heart failure or diabetic nephropathy.